SINTX secures patents in Europe, Canada, Japan and South Korea

SINTX Technologies (NASDAQ:SINT) announced two patent issuances and three allowances in Europe, Canada, Japan, and South Korea for its silicon nitride technologies. The patents cover coatings, manufacturing processes, and materials for medical and industrial uses. The company aims to expand commercially, leveraging its IP portfolio and recent facility upgrades. According to the CEO, robust IP protection is critical for this expansion.

Original reporting
Published Nov 17, 2026, 2:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 2:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$SINT
Bullish
medium confidence
Mentioned
$SINT
Relevance
5/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SINTBullishLow
01

Why it matters

The update expands the company’s intellectual property footprint across Europe, Canada, Japan, and South Korea for silicon nitride coatings and antifungal/antipathogenic fibrous material applications, supporting its stated commercialization plans.

02

Market read

Multi-jurisdiction IP progress can improve defensibility and investor confidence, but the article lacks financial magnitude or commercialization milestones.

03

What to watch

The article notes remaining grant-completion steps for some jurisdictions, and provides no information on claim breadth, enforcement strategy, or competitive landscape.

Relevance 5/10Novelty 5/10Timing: today’s headline IP update, no immediate financial datapoint

Background

SINTX develops and manufactures silicon nitride ceramic biomaterials and composites for medical and industrial applications, including coatings and antifungal composite materials.

Company-level read

Ticker impact

$SINTBullishMedium confidence
Context

SINTX announced two European EPO allowances, plus Japan, Canada, and South Korea patent issuances/allowances for its silicon nitride biomaterials and coatings.

Expected impact

Likely modest positive bias as investors price improved defensibility, though the lack of financial terms limits near-term upside.

Evidence & confidence

The article is a first-report style corporate update on IP status across several countries, but it provides no revenue, licensing, or milestone numbers tied to the patents.

Market effects

Reinforces the silicon nitride biomaterials IP pipeline theme for medical device materials and additive manufacturing-enabled coatings.

Signals progress toward commercialization readiness in Europe, Japan, Canada, and South Korea.

Multi-jurisdiction patent coverage can improve perceived global scalability for the platform, but impact is company-specific.

Counterpoint

Patent allowances and issuances do not guarantee commercial traction; without licensing deals or adoption metrics, the market may discount the news.

Key entities

  • SINTX Technologies, Inc.

    NASDAQ-listed silicon nitride biomaterials and composites developer that announced multi-country patent issuances/allowances.

  • European Patent Office

    Granted/allowed specific patent applications covering silicon nitride coatings and manufacturing processes.

  • Japan Patent Office

    Issued a patent for anti-pathogenic fibrous material using silicon nitride in sutures, face masks, and wound dressings.

  • Canada and South Korea patent authorities

    Issued/allowed patents in antifungal composite families combining silicon nitride with biocompatible polymers.

Related articles

$SINTMed

SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization

Sintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization Third quarter revenue increases more than tenfold year over year, while operating losses decrease 51% as Company advances commercialization of its proprietary silicon

$SINTMed

SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance

Sintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance Third-quarter revenue grows roughly 380% from Q2, driven by stronger-than-expected industrial sales to Fortune 500 customers; Company reiterates Q4 revenue guidance Revenue milestone

$SINTLow

SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives

Sintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives SALT LAKE CITY, Utah – August 11, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a

$SINTLow

Sintx Technologies (NASDAQ:SINT) Given “Buy” Rating at Maxim Group

Maxim Group reiterated a “Buy” rating on Sintx Technologies (NASDAQ:SINT) and set a $6.00 price target, implying 169.66% upside from the prior close, according to Benzinga. Other firms cited include Ascendiant (cut target to $12, Buy), Weiss (sell), and HC Wainwright (Buy, $10). SINT last traded at $2.23. The company reported Q EPS of ($0.70) vs ($0.66) consensus and revenue of $0.38M vs $0.30M.

$NNVCMed

NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox

NanoViricides, Inc. (NYSE American:NNVC) filed its Q3 2026 report, revealing Phase II trials for NV-387 Oral Gummies to treat Ebola and Mpox. The company has $2.98M in cash and $9.56M in total assets, but warns of insufficient funding for operations beyond November 2027.